Scapa Group PLC Directorate Change (2211B)

TIDMSCPA

RNS Number : 2211B

Scapa Group PLC

08 January 2018

8 January 2018

Scapa Group plc

('Scapa' or 'the Company')

Directorate Changes

Scapa Group plc (AIM: SCPA), a global supplier of bonding solutions and manufacturer of adhesive-based products for the Healthcare and Industrial markets, today announces the following directorate changes.

Mr Pierre Guyot will join the Board as an Independent Non-Executive Director with immediate effect, and will also become a member of the Board's Audit and Risk, Remuneration, and Nominations Committees upon his appointment. Mr Guyot has over 30 years' experience in the international healthcare industry and is currently a Director of Permobil AB, Sweden, and Peters Surgical SA, France. From January 2014 until 31 December 2017, Mr Guyot was a Director of Spineguard SA, France, and from 2007 to 2014, he was the Chief Executive Officer of Mölnlycke Health Care in Sweden. Prior to this, Mr Guyot served in various roles in sales and marketing and EMEA positions with Becton Dickinson, Johnson & Johnson, and Boston Scientific.

Mr Brendan McAtamney will join the Board as an Independent Non-Executive Director with effect from 1 February 2018, and will also become a member of the Board's Audit and Risk, Remuneration and Nominations Committees with effect from that date. Mr McAtamney was appointed Chief Executive Officer of UDG Healthcare on 2 February 2016, having served as an executive director since December 2013, and having originally joined UDG as Chief Operating Officer in 2013. Prior to that, Mr McAtamney has held various senior management positions with Abbott, latterly as Vice President Commercial and Corporate Officer within its Established Pharmaceuticals Division.

Mr Richard Perry, Senior Independent Non-Executive Director, who having served on the Board since 2005, has indicated that he does not intend to offer himself for re-election at the 2018 AGM.

Larry Pentz, Scapa Group Chairman, commented: "We are pleased to welcome Pierre and Brendan to the Board and look forward to leveraging the wealth of knowledge and experience they each bring to their roles. Although Richard Perry will continue in his role as the Senior Independent Director up until his retirement in July 2018, I would also like to take this opportunity to thank Richard for the advice and support he has given me as Chairman and for his contribution and commitment to the Company and the Board of Directors over the last twelve years."

Composition of Board Committees

The following table sets out the composition, following the implementation of the above appointments, of the Board Committees:-

 
 Committee               Chairman                 Members 
 Nominations       Lawrence Pentz         David Blackwood 
                                           Martin Sawkins 
                                            Richard Perry 
                                          Pierre Guyot(1) 
                                     Brendan McAtamney(2) 
 Remuneration      Martin Sawkins         David Blackwood 
                                            Richard Perry 
                                           Lawrence Pentz 
                                          Pierre Guyot(1) 
                                     Brendan McAtamney(2) 
 Audit and Risk   David Blackwood          Martin Sawkins 
                                            Richard Perry 
                                           Lawrence Pentz 
                                          Pierre Guyot(1) 
                                     Brendan McAtamney(2) 
 

(1) With effect from 8 January 2018

(2) With effect from 1 February 2018

The Company makes the following disclosures in relation to Mr Guyot's appointment in accordance with Rule 17 of and paragraph (g) of Schedule Two of the AIM Rules for Companies:

   1.            Director's full name: Pierre Roger Michel Guyot 

Director's age: 53 years

2. Other directorships / partnerships held during the last five years, including appointment and, where appropriate, resignation dates:

 
 Name of Company    Date appointed   Date resigned 
  / Partnership 
 
 SC Garonne            25 February              na 
                              2015 
 BSN Medical         1 August 2015    3 April 2017 
 Spineguard SA          15 January     31 December 
                              2014            2017 
 Peters Surgical         1 January              na 
  SA                          2014 
 Permobil AB            3 May 2013              na 
 Mölnlycke       10 July 2007   31 March 2014 
  Health Care Ltd 
 MHC UK Ltd            9 July 2007   31 March 2014 
 SSR Seven Ltd         15 May 2007              na 
 
   3.            Shareholding: Mr Guyot does not hold any shares in the Company. 

4. Other information: There is no other information required to be disclosed in relation to Mr Guyot under paragraph (g) of Schedule Two of the AIM Rules for Companies.

The Company makes the following disclosures in relation to Mr McAtamney's appointment in accordance with paragraph (g) of Schedule Two of the AIM Rules for Companies:

   1.            Director's full name: Brendan Patrick McAtamney 

Director's age: 55 years

2. Other directorships / partnerships held during the last five years, including appointment and, where appropriate, resignation dates:

 
  Name of Company/Partnership   Date appointed   Date resigned 
                                   16 December              na 
  UDG Healthcare plc                      2013 
  Aquilant Analytical              16 December              na 
   Sciences Ltd                           2013 
  Aquilant Medical                 16 December              na 
   (ROI) Ltd                              2013 
  Aquilant Scientific              16 December              na 
   (ROI) Ltd                              2013 
  UDG Healthcare Ireland           16 December              na 
   Ltd                                    2013 
  UDG Healthcare Ayrtons           16 December              na 
   (Dublin) Ltd                           2013 
                                    30 October              na 
  Aquilant Ltd                            2013 
  Aquilant Scientific               30 October              na 
   (UK) Ltd                               2013 
  Ashfield Healthcare               3 February              na 
   Ltd                                    2016 
  Unitech Equipment                 30 October              na 
   Ltd                                    2013 
  UDG Healthcare (UK)              1 June 2015              na 
   Holdings Ltd 
  Abbott Laboratories              31 May 2010         31 July 
   GmbH                                                   2013 
  Abbott Products                  31 May 2010         31 July 
   GmbH                                                   2013 
                                   28 February         31 July 
  Abbott Laboratories                     2010            2013 
  Abbott Laboratories              28 February         31 July 
   Inc                                    2010            2013 
  Laboratoires Fournier            31 May 2010       8 January 
   S.A.S                                                  2013 
  Abbott Truecare                  31 May 2010         31 July 
   Pharma Private Ltd                                     2013 
 
 
   3.            Shareholding: Mr McAtamney does not hold any shares in the Company. 

4. Other information: There is no other information required to be disclosed in relation to Mr McAtamney under paragraph (g) of Schedule Two of the AIM Rules for Companies.

For further information:

Scapa Group plc:

Wendy Baker [phone]

Group General Counsel and Company Secretary

Numis Securities Limited: [phone]

Mark Lander

Richard Thomas (Nominated Adviser)

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOASSAFSAFASESF

(END) Dow Jones Newswires

January 08, 2018 05:10 ET (10:10 GMT)